Featured Publications
Cell Death in the Lung: The Apoptosis–Necroptosis Axis
Sauler M, Bazan IS, Lee PJ. Cell Death in the Lung: The Apoptosis–Necroptosis Axis. Annual Review Of Physiology 2018, 81: 1-28. PMID: 30485762, PMCID: PMC6598441, DOI: 10.1146/annurev-physiol-020518-114320.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsRegulated cell deathCell deathAutophagic cell deathCell death mechanismsSuperfluous cellsAcute respiratory distress syndromeChronic obstructive pulmonary diseasePulmonary arterial hypertensionIdiopathic pulmonary fibrosisObstructive pulmonary diseaseRespiratory distress syndromeDeath mechanismsCellular mechanismsArterial hypertensionDistress syndromePulmonary diseasePulmonary fibrosisPulmonary disordersMajor mechanismDeathNew modalityPathogenesisNecroptosisMechanismApoptosis
2017
Complexity of macrophage migration inhibitory factor (MIF) and other angiogenic biomarkers profiling in pulmonary arterial hypertension
Marshall JD, Sauler M, Tonelli A, Rao Y, Bucala R, Lee PJ, Fares WH. Complexity of macrophage migration inhibitory factor (MIF) and other angiogenic biomarkers profiling in pulmonary arterial hypertension. Pulmonary Circulation 2017, 7: 730-733. PMID: 28714356, PMCID: PMC5841895, DOI: 10.1177/2045893217724141.Peer-Reviewed Original ResearchMacrophage migration inhibitory factorMigration inhibitory factorInhibitory factorPulmonary arterial hypertension patientsPulmonary arterial hypertensionArterial hypertension patientsArterial hypertensionHypertension patientsAngiogenic biomarkersAngiogenic factorsSignificant positive correlationBiomarkersPositive correlationRegulation roleHypertensionPatientsFactorsPathobiology
2013
Standard Nonspecific Therapies in the Management of Pulmonary Arterial Hypertension
Sauler M, Fares WH, Trow TK. Standard Nonspecific Therapies in the Management of Pulmonary Arterial Hypertension. Clinics In Chest Medicine 2013, 34: 799-810. PMID: 24267305, DOI: 10.1016/j.ccm.2013.08.013.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsHigh-dose calcium channel blockersCommon cardiopulmonary diseasesPAH-specific therapyPulmonary arterial hypertensionTreatment of patientsCalcium channel blockersPAH therapyArterial hypertensionAdjunct therapyOxygen therapyMedical therapyNonspecific therapyCardiopulmonary diseasePathologic understandingChannel blockersSmall studyTherapyHypertension researchExpert opinionAnticoagulationHypertensionDiureticsPatientsBlockersDigoxin